Glimcher is taking what may be the greatest risk of her career: breaking up a decades-long partnership with Brigham & Women’s Hospital and inking a deal for with Beth Israel Deaconess Medical Center to build a 300-bed Dana-Farber cancer hospital.
On July 7, 2022, invoX Pharma Limited ("invoX"), a wholly owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK) commenced a cash tender offer for all of the issued and